Overview

Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer

Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effectiveness of the combination of abemaciclib and fulvestrant in treating this type of cancer and to determine the types and severity of side effects caused by treatment with abemaciclib and fulvestrant.
Phase:
Phase 2
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborator:
Eli Lilly and Company
Treatments:
Estradiol
Fulvestrant